UPDATE: Roth Capital Resumes Coverage On Conatus Pharmaceuticals
In a report published today, Roth Capital analyst Ed Arce resumed coverage on Conatus Pharmaceuticals Inc. (CNAT) with a Buy rating and $19.00 price target.
Conatus’ sole asset, emricasan, is a first-in-class, oral pan-caspase inhibitor with a unique dual mechanism of action: inhibiting both the inflammation and apoptosis of liver disease.
Ed Arce: “In its first year post-IPO, Conatus is still a relative unknown, in our view, as Gilead Sciences’ (GILD) Sovaldi in HCV, and more recently, Intercept’s OCA in NASH, have effectively garnered all the attention in liver disease treatment. However, we believe positive results from two Phase II readouts later this year in ACLF and NASH should begin to raise the visibility of emricasan’s unique therapeutic profile, and with it, CNAT shares. With a sub-$120M market capitalization and an enterprise value under $70M, we find the shares compelling at these levels”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, Ed Arce, who covers CNAT, currently has a one-year average return of 28.4% and a 60% success rate.